Description
A potent COMT inhibitor (IC50 = 12 nM); selective for COMT over tyrosine hydroxylase, dopamine β-hydroxylase, dopamine decarboxylase, MAO-A, and MAO-B (IC50s = >14 µM for all); reduces 3-OMD levels in rat serum when administered in combination with L-DOPA and carbidopa compared with control animals receiving only L-DOPA and carbidopa at 30 mg/kg; chronic administration induces COMT-dependent thermal hyperalgesia and increases preference for dark in a light/dark preference test in rats at 15 mg/kg per day for seven days